These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21147986)

  • 1. An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease.
    Laganiere J; Kells AP; Lai JT; Guschin D; Paschon DE; Meng X; Fong LK; Yu Q; Rebar EJ; Gregory PD; Bankiewicz KS; Forsayeth J; Zhang HS
    J Neurosci; 2010 Dec; 30(49):16469-74. PubMed ID: 21147986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
    Eslamboli A; Georgievska B; Ridley RM; Baker HF; Muzyczka N; Burger C; Mandel RJ; Annett L; Kirik D
    J Neurosci; 2005 Jan; 25(4):769-77. PubMed ID: 15673656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
    Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
    Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.
    Tereshchenko J; Maddalena A; Bähr M; Kügler S
    Neurobiol Dis; 2014 May; 65():35-42. PubMed ID: 24440408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.
    Fjord-Larsen L; Johansen JL; Kusk P; Tornøe J; Grønborg M; Rosenblad C; Wahlberg LU
    Exp Neurol; 2005 Sep; 195(1):49-60. PubMed ID: 15919076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
    Andereggen L; Meyer M; Guzman R; Ducray AD; Widmer HR
    Brain Res; 2009 Jun; 1276():39-49. PubMed ID: 19389387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
    Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
    Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
    Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
    Lapchak PA; Araujo DM; Hilt DC; Sheng J; Jiao S
    Brain Res; 1997 Nov; 777(1-2):153-60. PubMed ID: 9449424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
    Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
    Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
    Georgievska B; Kirik D; Rosenblad C; Lundberg C; Björklund A
    Neuroreport; 2002 Jan; 13(1):75-82. PubMed ID: 11924898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease.
    Yasuhara T; Shingo T; Muraoka K; Kobayashi K; Takeuchi A; Yano A; Wenji Y; Kameda M; Matsui T; Miyoshi Y; Date I
    J Neurosurg; 2005 Jan; 102(1):80-9. PubMed ID: 15658100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrastriatal GDNF gene transfer by inducible lentivirus vectors protects dopaminergic neurons in a rat model of parkinsonism.
    Chen SS; Yang C; Hao F; Li C; Lu T; Zhao LR; Duan WM
    Exp Neurol; 2014 Nov; 261():87-96. PubMed ID: 24997241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease.
    Hoban DB; Howard L; Dowd E
    Neuroscience; 2015 Sep; 303():402-11. PubMed ID: 26166730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
    Connor B
    Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model of GDNF gene therapy in mice with 6-Hydroxydopamine lesions: time course of Neurorestorative effects and ERK1/2 activation.
    Lindgren N; Francardo V; Quintino L; Lundberg C; Cenci MA
    J Parkinsons Dis; 2012; 2(4):333-48. PubMed ID: 23938263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons.
    Sterky FH; Pernold K; Harvey BK; Lindqvist E; Hoffer BJ; Olson L
    Cell Transplant; 2013; 22(9):1529-39. PubMed ID: 23051605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.